ActionsFrom an ethical perspective, in this scenario, one of the likely actions as a statistical analyst would be to strive to ensure the relevance of my statistical analyses. Normally, every new drug research and design relies on a thorough understanding of the statistical procedures and thematic questions that are undoubtedly described at each stage. The second likely action as an analyst is to be wary of the possibility that bias on the part of data providers or researchers could predict the outcome of the analysis. The third likely action in this scenario as a statistical analyst would be to use analytical approaches designed to ensure valid statistical analysis. At the same time, as an analyst, it would be appropriate to use statistical methods appropriate to the available data to achieve valid results. Additionally, be careful when drawing analytical conclusions. Additionally, as a statistical analyst, it would be advisable to disclose conflicts of interest with my supervisor to resolve them. This may sometimes involve withdrawing from the analytical process. As an analyst, all of these actions are aimed at taking personal responsibility for the statistical analysis process. In light of this, statistical knowledge is essential throughout the drug research and development process, from designing a study to answer the hypothesis to presenting study results to agencies. regulatory authorities, drug distributors and the clinical community. the analyst (employee of the company) is a stakeholder and is professionally required to respect widely accepted statistical protocols; despite the supervisor's instructions to ignore the 5% of the sample who do not show improvement in their medical condition...... middle of paper ...... and drug development. Furthermore, the crucial objective of the ethical use of statistics in the development of new drug research is to conventionally establish whether or not there is convincing evidence that the new drug being researched and design is both effective and safe. Additionally, the data obtained in a clinical trial are not just numbers, but a digital representation of biologically meaningful information. In this scenario, compelling evidence may be considered satisfactory evidence for a regulator. If there is satisfactory evidence, the new drug will be approved for marketing and will further become available for prescription by clinicians when treating patients. Works Cited Ethical Guidelines for Statistical Practice by the American Statistical Association Turner, J R. New Drug Development: An Introduction to Clinical Trials. New York: Springer, 2010. Print.